[About the safety of application of nasal decongestants in the practice of pediatricians].

Undesirable effects of the application of the intransal vasoconstricting medications are a frequent occurrence in the pediatric practice. The objective of the present study was to evaluate the role of the intranasal vasoconstricting medications in the structure of the means and methods currently available for the treatment of toxicological pathologies based at a multi-field clinical hospital. The retrospective analysis of the medical histories of the patients admitted to the toxicological department and annual reports for the period from 2015 to 2016 was undertaken.

[Innovation in differential diagnosis and monitoring of rational therapy in patients with lumbosacral radiculopathies].

Objective: Unfortunately, nowadays there are no reliable ways to predict the outcomes of the conservative treatment in patients with dorsopathies. Otherwise, we could identify patients that demand intensive treatment including therapeutic blockades. We approbated and modified a method for assessment of radicular latency duration in patients with lumbosacral radiculopathies to evaluate its diagnostic value and the possibility of using in monitoring of effectiveness of conservative treatment.

[Hypotensive efficacy of combined pathogenically oriented surgical treatment of cataract and primary open-angle glaucoma].

A new algorithm of combined surgical treatment of cataract and glaucoma was developed. It enables selection of a proper method of pathogenically oriented antiglaucomatous intervention, decreases surgical trauma, facilitates normalization of intraocular pressure and helps stabilizing the course of the disease. Another development is a modification of combined phacoemulsification and trabeculectomy ab interno, aimed at increasing visual and hypotensive results.

[Metabolic therapy in neurology].

We studied the efficacy of rheosorbilact, an original infusion drug based on polyalcohols, in the complex therapy of patients with brain ischemia and diabetic neuropathy. Reosorbilact was used intravenously indrops 200-400 ml in day - 20 days. The primary endpoint of the study was the improvement of quality of life assessed with the SF-36 scale after 1 month of treatment.